Breaking News
Investing Pro 0
🚨 NDVA surged 43%. This AI Chipmaker Could Be Next See Analysis

Noxopharm welcomes preliminary data on Veyonda drug trial

Published May 26, 2023 09:30 Updated May 26, 2023 10:00
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. Noxopharm welcomes preliminary data on Veyonda drug trial

Noxopharm Ltd (ASX:NOX, OTC:NOXOF) has welcomed preliminary data of its oncology drug candidate Veyonda®, currently in trial in combination with Bristol Myers Squibb’s immune checkpoint inhibitor (ICI) Opdivo® (nivolumab) for the treatment of cancer.

Initial results from the first phase of the IONIC investigator-initiated pilot trial show promising tumour responses, with no safety signals evident to date.

Eleven patients with advanced tumour types including lung, prostate, gastric, pancreatic, nasopharyngeal and metastatic squamous carcinoma have received at least two cycles of the combination treatment, with two completing eight cycles and two remaining on study.

Fighting cancer

The aim of the study is to increase the activity of nivolumab by using Veyonda to overcome tumour resistance to ICI therapy.

Up to 30 patients across six sites in the Sydney area and regional New South Wales will participate in the study, which involves an initial dose escalation phase followed by dose expansion.

The trial is being led by principal investigator Professor Paul de Souza, a consultant medical oncologist, a Professor of Medicine at the University of Sydney based at the Nepean Cancer Centre, a conjoint Professor in the Faculty of Medicine, UNSW Australia, and a former Foundation Professor of Medical Oncology at Western Sydney University.

Abstract published

An abstract of the data has been published online for the American Society of Clinical Oncology (ASCO) annual meeting taking place in Chicago from 2-6 June.

ASCO is the world's leading professional organisation for physicians and oncology professionals caring for people with cancer, and its annual meeting is the world’s largest gathering of oncology physicians, industry representatives, researchers, patient advocates and investment analysts.

Click here for the abstract of the study.

Pioneering life-changing therapies

Noxopharm is developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines.

The biotech company uses specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms, Chroma™ for oncology and Sofra™ for inflammation, autoimmunity, and mRNA vaccine enhancement.

Noxopharm also has a major shareholding in US biotech company Nyrada (ASX:NYR) Inc, which focuses on drug development for cardiovascular and neurological diseases.

Read more on Proactive Investors AU

Disclaimer

Noxopharm welcomes preliminary data on Veyonda drug trial
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email